Special Issue

The Many Faces of Huntington Disease

Message from the Guest Editor

Huntington disease (HD) is a rare, neurological, genetic, dominantly transmitted illness affecting adults and, more rarely, children. HD represents a study model for other well-known neurodegenerative diseases, such as Alzheimer, Parkinson and Amyotrophic Lateral Sclerosis, because it overlaps their symptoms and is always caused by a single known gene mutation. Different from most other neurodegenerative diseases, the mutation can be easily detected by a worldwide available genetic test as early as the premanifest life stage. This *Journal of Personalized Medicine* Special Issue aims to highlight the current state of the science on the clinical and genetic variability of HD, including the impact of the disease development on social burden. Studies include those that explore the many faces of cognitive, behavioral, motor and genetic changes in premanifest and manifest adulthood and pediatric HD. The scientific advances in the field of the phenotype variability and its potential relationship with biological changes pave the path towards personalized medicine for HD as a model for many other neurological diseases.

Guest Editor

Prof. Dr. Ferdinando Squitieri

Huntington and Rare Diseases Unit at CSS-Mendel Institute of IRCCS Casa Sollievo della Sofferenza Research Hospital, Rome, Italy

Deadline for manuscript submissions

closed (25 December 2022)

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed

mdpi.com/si/81776

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/jpm

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed

mdpi.com/journal/jpm

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical
subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker
Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).

MDPI